Proteogenomic examination of esophageal squamous cell carcinoma (ESCC): new lines of inquiry

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–1953.
   PubMed Web of Science ®Google Scholar
• Chang JT, Katzka DA. Gastroesophageal reflux disease, Barrett esophagus, and esophageal adenocarcinoma. Arch Intern Med. 2004;164(14):1482–1488.
   PubMedGoogle Scholar
• Nesvizhskii AI. Proteogenomics: concepts, applications and computational strategies. Nat Methods. 2014;11(11):1114–1125.
   PubMed Web of Science ®Google Scholar
• Renuse S, Chaerkady R, Pandey A. Proteogenomics. Proteomics. 2011 Feb;11(4):620–630.
   PubMed Web of Science ®Google Scholar
• Mertins P, Mani DR, Ruggles KV, et al. Proteogenomics connects somatic mutations to signalling in breast cancer. Nature. 2016;534(7605):55–62.
   PubMed Web of Science ®Google Scholar
• Ali HR, Rueda OM, Chin SF, et al. Genome-driven integrated classification of breast cancer validated in over 7,500 samples. Genome Biol. 2014;15(8):431.
   PubMed Web of Science ®Google Scholar
• Talseth-Palmer BA, Scott RJ. Genetic variation and its role in malignancy. Int J Biomed Sci. 2011;7(3):158–171.
   PubMedGoogle Scholar
• Pawar H, Kashyap MK, Sahasrabuddhe NA, et al. Quantitative tissue proteomics of esophageal squamous cell carcinoma for novel biomarker discovery. Cancer Biol Ther. 2011;12(6):510–522.
   PubMed Web of Science ®Google Scholar
• Mir SA, Rajagopalan P, Jain AP, et al. LC-MS-based serum metabolomic analysis reveals dysregulation of phosphatidylcholines in esophageal squamous cell carcinoma. J Proteomics. 2015;127(Pt A):96–102.
   PubMedGoogle Scholar
• Kashyap MK, Harsha HC, Renuse S, et al. SILAC-based quantitative proteomic approach to identify potential biomarkers from the esophageal squamous cell carcinoma secretome. Cancer Biol Ther. 2010;10(8):796–810.
   PubMed Web of Science ®Google Scholar
• Schwacke J, Millar TP, Hammond CE, et al. Discrimination of normal and esophageal cancer plasma proteomes by MALDI-TOF mass spectrometry. Dig Dis Sci. 2015;60(6):1645–1654.
   PubMed Web of Science ®Google Scholar
• Wang LD, Wang DC, Zheng S, et al. Serum proteomic profiles of the subjects with esophageal precancerous and cancerous lesions from Linzhou, an area with high incidence of esophageal cancer in Henan Province, Northern China. Ai Zheng. 2006;25(5):549–554.
   PubMedGoogle Scholar
• Uemura N, Nakanishi Y, Kato H, et al. Antibody-based proteomics for esophageal cancer: identification of proteins in the nuclear factor-kappaB pathway and mitotic checkpoint. Cancer Sci. 2009a;100(9):1612–1622.
   PubMed Web of Science ®Google Scholar
• Qi YJ, He QY, Ma YF, et al. Proteomic identification of malignant transformation-related proteins in esophageal squamous cell carcinoma. J Cell Biochem. 200;104(5):1625–1635.
   Google Scholar
• Nishimori T, Tomonaga T, Matsushita K, et al. Proteomic analysis of primary esophageal squamous cell carcinoma reveals downregulation of a cell adhesion protein, periplakin. Proteomics. 2006;6(3):1011–1018.
   PubMed Web of Science ®Google Scholar
• Katoh Y, Katoh M. Comparative integromics on Ephrin family. Oncol Rep. 2006;15(5):1391–1395.
   PubMed Web of Science ®Google Scholar
• Zhang Y. Epidemiology of esophageal cancer. World J Gastroenterol. 2013;19(34):5598–5606.
   PubMed Web of Science ®Google Scholar
• Zhao J, Fan YX, Yang Y, et al. Identification of potential plasma biomarkers for esophageal squamous cell carcinoma by a proteomic method. Int J ClinExpPathol. 2015;8(2):1535–1544.
   Web of Science ®Google Scholar
• Wang X, Peng Y, Xie M, et al. Identification of extracellular matrix protein 1 as a potential plasma biomarker of ESCC by proteomic analysis using iTRAQ and 2D-LC-MS/MS. Proteomics Clin Appl.. 2017;11(9–10):1600163.
   Web of Science ®Google Scholar
• Nambu M, Masuda T, Ito S, et al. Leucine-rich alpha-2-glycoprotein 1 in serum is a possible biomarker to predict response to preoperative chemoradiotherapy for esophageal cancer. Biol Pharm Bull. 2019;42(10):1766–1771.
   PubMed Web of Science ®Google Scholar
• Zhai XH, Yu JK, Lin C, et al. Combining proteomics, serum biomarkers and bioinformatics to discriminate between esophageal squamous cell carcinoma and pre-cancerous lesion. J Zhejiang UnivSci B. 2012;13(12):964–971.
   PubMed Web of Science ®Google Scholar
• Xu SY, Liu Z, Ma WJ, et al. New potential biomarkers in the diagnosis of esophageal squamous cell carcinoma. Biomarkers. 2009;14(5):340–346.
   PubMed Web of Science ®Google Scholar
• Liu WL, Zhang G, Wang JY, et al. Proteomics-based identification of autoantibody against CDC25B as a novel serum marker in esophageal squamous cell carcinoma. Biochem Biophys Res Commun. 2008;375(3):440–445.
   PubMed Web of Science ®Google Scholar
• Fujita Y, Nakanishi T, Miyamoto Y, et al. Proteomics-based identification of autoantibody against heat shock protein 70 as a diagnostic marker in esophageal squamous cell carcinoma. Cancer Lett. 2008;263(2):280–290.
   PubMed Web of Science ®Google Scholar
• Fujita Y, Nakanishi T, Hiramatsu M, et al. Proteomics-based approach identifying autoantibody against peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma. Clin Cancer Res. 2006;12(21):6415–6420.
   PubMed Web of Science ®Google Scholar
• An JY, Fan ZM, Zhuang ZH, et al. Proteomic analysis of blood level of proteins before and after operation in patients with esophageal squamous cell carcinoma at high-incidence area in henan province. World J Gastroenterol. 2004;10(22):3365–3368.
   PubMed Web of Science ®Google Scholar
• Ma XL, Yao H, Wang X, et al. ILK predicts the efficacy of chemoradiotherapy and the prognosis of patients with esophageal squamous cell carcinoma. Oncol Lett. 2019;18(4):4114–4125.
   PubMed Web of Science ®Google Scholar
• Qi Y, Chiu JF, Wang L, et al. Comparative proteomic analysis of esophageal squamous cell carcinoma. Proteomics. 2005;5(11):2960–2971.
   PubMed Web of Science ®Google Scholar
• Du XL, Hu H, Lin DC, et al. Proteomic profiling of proteins dysregulted in Chinese esophageal squamous cell carcinoma. J Mol Med (Berl). 2007;85(8):863–875.
   PubMed Web of Science ®Google Scholar
• Hatakeyama H, Kondo T, Fujii K, et al. Protein clusters associated with carcinogenesis, histological differentiation and nodal metastasis in esophageal cancer. Proteomics. 2006;6(23):6300–6316.
   PubMed Web of Science ®Google Scholar
• Ning Z, Zhu X, Jiang Y, et al. Integrin-linked kinase is involved in the proliferation and invasion of esophageal squamous cell carcinoma. J Cancer. 2020;11(2):324–333.
   PubMed Web of Science ®Google Scholar
• Yu SB, Gao Q, Lin WW, et al. Proteomic analysis indicates the importance of TPM3 in esophageal squamous cell carcinoma invasion and metastasis. Mol Med Rep. 2017;15(3):1236–1242.
   PubMed Web of Science ®Google Scholar
• Deng F, Zhou K, Li Q, et al. iTRAQ-based quantitative proteomic analysis of esophageal squamous cell carcinoma. Tumour Biol. 2016;37(2):1909–1918.
   PubMedGoogle Scholar
• Xu X, Song C, Chen Z, et al. Downregulation of HuR inhibits the progression of esophageal cancer through interleukin-18. Cancer Res Treat. 2018;50(1):71–87.
   PubMed Web of Science ®Google Scholar
• Mrena J, Wiksten JP, Thiel A, et al. Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factor HuR. Clin Cancer Res. 2005;11(20):7362–7368.
   PubMed Web of Science ®Google Scholar
• Denkert C, Koch I, von Keyserlingk N, et al. Expression of the ELAV-like protein HuR in human colon cancer: association with tumor stage and cyclooxygenase-2. Mod Pathol. 2006;19(9):1261–1269.
   PubMed Web of Science ®Google Scholar
• Heinonen M, Fagerholm R, Aaltonen K, et al. Prognostic role of HuR in hereditary breast cancer. Clin Cancer Res. 2007;13(23):6959–6963.
   PubMed Web of Science ®Google Scholar
• Williams TK, Costantino CL, Bildzukewicz NA, et al. pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAs. PLoS One. 2010;5(11):e15455.
   PubMedGoogle Scholar
• Romeo C, Weber MC, Zarei M, et al. HuR contributes to TRAIL resistance by restricting death receptor 4 expression in pancreatic cancer cells. Mol Cancer Res. 2016;14(7):599–611.
   PubMed Web of Science ®Google Scholar
• Latorre E, Tebaldi T, Viero G, et al. Downregulation of HuR as a new mechanism of doxorubicin resistance in breast cancer cells. Mol Cancer. 2012;11:13.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhi C, Zhen F, et al. iTRAQ-based quantitative proteomic analyses of high grade esophageal squamous intraepithelial neoplasia. Proteomics Clin Appl. 2017;11:11–12.
   Web of Science ®Google Scholar
• Pawar H, Maharudraiah J, Kashyap MK, et al. Downregulation of cornulin in esophageal squamous cell carcinoma. ActaHistochem. 2013;115(2):89–99.
   Google Scholar
• Chen K, Li Y, Dai Y, et al. Characterization of tumor suppressive function of cornulin in esophageal squamous cell carcinoma. PLoS One. 2013;8(7):e68838.
   PubMed Web of Science ®Google Scholar
• Hsu PK, Kao HL, Chen HY, et al. Loss of CRNN expression is associated with advanced tumor stage and poor survival in patients with esophageal squamous cell carcinoma. J ThoracCardiovasc Surg. 2014;147(5):1612–1618 e4.
   Web of Science ®Google Scholar
• Feng JG, Liu Q, Qin X, et al. Clinicopathological pattern and Annexin A2 and Cdc42 status in patients presenting with differentiation and lymphnode metastasis of esophageal squamous cell carcinomas. MolBiol Rep. 2012;39(2):1267–1274.
   PubMed Web of Science ®Google Scholar
• Qi YJ, Wang LD, Jiao XY, et al. Dysregulation of Annexin II expression in esophageal squamous cell cancer and adjacent tissues from a high-incidence area for esophageal cancer in Henan province. Ai Zheng. 2007;26(7):730–736.
   PubMedGoogle Scholar
• Singhal R, Carrigan JB, Wei W, et al. MALDI profiles of proteins and lipids for the rapid characterisation of upper GI-tract cancers. J Proteomics. 2013 27;80:207–215.
   PubMed Web of Science ®Google Scholar
• Uemura N, Nakanishi Y, Kato H, et al. Transglutaminase 3 as a prognostic biomarker in esophageal cancer revealed by proteomics. Int J Cancer. 2009b;124(9):2106–2115.
   PubMed Web of Science ®Google Scholar
• Fu L, Qin YR, Xie D, et al. Identification of alpha-actinin 4 and 67 kDalaminin receptor as stage-specific markers in esophageal cancer via proteomic approaches. Cancer. 2007;110(12):2672–2681.
   PubMed Web of Science ®Google Scholar
• Jazii FR, Najafi Z, Malekzadeh R, et al. Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer. World J Gastroenterol. 2006;12(44):7104–7112.
   PubMed Web of Science ®Google Scholar
• Chen HB, Pan K, Tang MK, et al. Comparative proteomic analysis reveals differentially expressed proteins regulated by a potential tumor promoter, BRE, in human esophageal carcinoma cells. Biochem Cell Biol. 2008;86(4):302–311.
   PubMed Web of Science ®Google Scholar
• Islam F, Gopalan V, Lam AK. Mass spectrometry for biomarkers discovery in esophageal squamous cell carcinoma. Methods Mol Biol. 2020;2129:259–268.
   PubMedGoogle Scholar
• Xu F, Zhang S, Liu Z, et al. TEX9 and eIF3b functionally synergize to promote the progression of esophageal squamous cell carcinoma. BMC Cancer. 2019;19(1):875.
   PubMed Web of Science ®Google Scholar
• Moghanibashi M, RastgarJazii F, Soheili ZS, et al. Esophageal cancer alters the expression of nuclear pore complex binding protein Hsc70 and eIF5A-1. FunctIntegr Genomics. 2013;13(2):253–260.
   Web of Science ®Google Scholar
• Moghanibashi M, Jazii FR, Soheili ZS, et al. Proteomics of a new esophageal cancer cell line established from Persian patient. Gene. 2012;500(1):124–133.
   PubMed Web of Science ®Google Scholar
• Wen J, Zheng B, Hu Y, et al. Comparative proteomic analysis of the esophageal squamous carcinoma cell line EC109 and its multi-drug resistant subline EC109/CDDP. Int J Oncol. 2010;36(1):265–274.
   PubMed Web of Science ®Google Scholar
• Datta KK, Patil S, Patel K, et al. Chronic exposure to chewing tobacco induces metabolic reprogramming and cancer stem cell-like properties in esophageal epithelial cells. Cells. 2019;8(9):949.
   PubMed Web of Science ®Google Scholar
• Tsai ST, Wang PJ, Liou NJ, et al. ICAM1 Is a potential cancer stem cell marker of esophageal squamous cell carcinoma. PLoS One. 2015;10(11):e0142834.
   PubMed Web of Science ®Google Scholar
• Hayashida Y, Honda K, Osaka Y, et al. Possible prediction of chemoradiosensitivity of esophageal cancer by serum protein profiling. Clin Cancer Res. 2005;11(22):8042–8047.
   PubMed Web of Science ®Google Scholar
• Sun Y, Zhai L, Ma S, et al. Down-regulation of RIP3 potentiates cisplatin chemoresistance by triggering HSP90-ERK pathway mediated DNA repair in esophageal squamous cell carcinoma. Cancer Lett. 2018;418:97–108.
   PubMed Web of Science ®Google Scholar
• Li C, Xia G, Jianqing Z, et al. Serum differential protein identification of Xinjiang Kazakh esophageal cancer patients based on the two-dimensional liquid-phase chromatography and LTQ MS. MolBiol Rep. 2014;41(5):2893–2905.
   PubMed Web of Science ®Google Scholar
• Zhang C, Zhang J, Wu Q, et al. Sulforaphene induces apoptosis and inhibits the invasion of esophageal cancer cells through MSK2/CREB/Bcl-2 and cadherin pathway in vivo and in vitro. Cancer Cell Int. 2019;19:342.
   PubMed Web of Science ®Google Scholar
• Yang J, Dou Z, Peng X, et al. Transcriptomics and proteomics analyses of anti-cancer mechanisms of TR35-An active fraction from Xinjiang Bactrian camel milk in esophageal carcinoma cell. ClinNutr. 2019;38(5):2349–2359.
   Google Scholar
• Zheng WB, Li YJ, Wang Y, et al. Propafenone suppresses esophageal cancer proliferation through inducing mitochondrial dysfunction. Am J Cancer Res. 2017;7(11):2245–2256.
   PubMed Web of Science ®Google Scholar
• Zhang X, Li X, Zheng L, et al. ANXA1 silencing increases the sensitivity of cancer cells to low-concentration arsenic trioxide treatment by inhibiting ERK MAPK activation. Tumori. 2015;101(4):360–367.
   PubMed Web of Science ®Google Scholar
• Li LY, Zhang K, Jiang H, et al. Quantitative proteomics reveals the downregulation of GRB2 as a prominent node of F806-targeted cell proliferation network. J Proteomics. 2015;117:145–155.
   PubMed Web of Science ®Google Scholar
• Du P, Huang P, Huang X, et al. Comprehensive genomic analysis of oesophageal squamous cell carcinoma reveals clinical relevance. Sci Rep. 2017;7(1):15324.
   PubMedGoogle Scholar
• Wang Y, Wang G, Ma Y, et al. FAT1, a direct transcriptional target of E2F1, suppresses cell proliferation, migration and invasion in esophageal squamous cell carcinoma. Chin J Cancer Res. 2019;31(4):609–619.
   PubMed Web of Science ®Google Scholar
• Wang Q, Bai J, Abliz A, et al. An old story retold: loss of G1 control defines a distinct genomic subtype of esophageal squamous cell carcinoma. Genomics Proteomics Bioinformatics. 2015;13(4):258–270.
   PubMed Web of Science ®Google Scholar
• Kashyap MK, Marimuthu A, Kishore CJ, et al. Genomewide mRNA profiling of esophageal squamous cell carcinoma for identification of cancer biomarkers. Cancer Biol Ther. 2009;8(1):36–46.
   PubMed Web of Science ®Google Scholar
• Li Y, Nie CJ, Hu L, et al. Characterization of a novel mechanism of genomic instability involving the SEI1/SET/NM23H1 pathway in esophageal cancers. Cancer Res. 2010;70(14):5695–5705.
   PubMed Web of Science ®Google Scholar
• Tang DJ, Hu L, Xie D, et al. Oncogenic transformation by SEI-1 is associated with chromosomal instability. Cancer Res. 2005;65(15):6504–6508.
   PubMed Web of Science ®Google Scholar
• Chen FF, Zhang SR, Peng H, et al. Integrative genomics analysis of hub genes and their relationship with prognosis and signaling pathways in esophageal squamous cell carcinoma. Mol Med Rep. 2019;20(4):3649–3660.
   PubMed Web of Science ®Google Scholar
• Bhushan A, Singh A, Kapur S, et al. Identification and validation of fibroblast growth factor 12 gene as a novel potential biomarker in esophageal cancer using cancer genomic datasets. OMICS. 2017;21(10):616–631.
   PubMed Web of Science ®Google Scholar
• Im WR, Lee HS, Lee YS, et al. A Regulatory Noncoding RNA, nc886, Suppresses Esophageal Cancer by Inhibiting the AKT Pathway and Cell Cycle Progression. Cells. 2020;9(4):801.
   Web of Science ®Google Scholar
• Rong H, Chen B, Ma K, et al. Downregulation of lncRNA LINC-PINT participates in the recurrence of esophageal squamous cell carcinoma possibly by interacting miRNA-21. Cancer BiotherRadiopharm. 2020.
   Google Scholar
• Luo A, Zhou X, Shi X, et al. Exosome-derived miR-339-5p mediates radiosensitivity by targeting Cdc25A in locally advanced esophageal squamous cell carcinoma. Oncogene. 2019;38(25):4990–5006.
   PubMed Web of Science ®Google Scholar
• Lin WC, Chen LH, Hsieh YC, et al. miR-338-5p inhibits cell proliferation, colony formation, migration and cisplatin resistance in esophageal squamous cancer cells by targeting FERMT2. Carcinogenesis. 2019;40(7):883–892.
   PubMed Web of Science ®Google Scholar
• Shimonosono M, Idichi T, Seki N, et al. Molecular pathogenesis of esophageal squamous cell carcinoma: identification of the antitumor effects of miR1453p on gene regulation. Int J Oncol. 2019;54(2):673–688.
   PubMed Web of Science ®Google Scholar
• Zhang W, Hong R, Li L, et al. The chromosome 11q13.3 amplification associated lymph node metastasis is driven by miR-548k through modulating tumor microenvironment. Mol Cancer. 2018;17(1):125.
   PubMedGoogle Scholar
• Peng L, Cheng S, Lin Y, et al. CCGD-ESCC: a comprehensive database for genetic variants associated with esophageal squamous cell carcinoma in chinese population. Genomics Proteomics Bioinformatics. 2018;16(4):262–268.
   PubMed Web of Science ®Google Scholar
• Xu J, Chen Y, Zhang R, et al. Global and targeted metabolomics of esophageal squamous cell carcinoma discovers potential diagnostic and therapeutic biomarkers. Mol Cell Proteomics. 2013;12(5):1306–1318.
   PubMed Web of Science ®Google Scholar
• Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet. 2007;8(4):286–298.
   PubMed Web of Science ®Google Scholar
• Zhang K, Li L, Zhu M, et al. Comparative analysis of histone H3 and H4 post-translational modifications of esophageal squamous cell carcinoma with different invasive capabilities. J Proteomics. 2015;112:180–189.
   PubMed Web of Science ®Google Scholar
• Syed N, Barbhuiya MA, Pinto SM, et al. Phosphotyrosine profiling identifies ephrin receptor A2 as a potential therapeutic target in esophageal squamous-cell carcinoma. Proteomics. 2015;15(2–3):374–382.
   PubMed Web of Science ®Google Scholar
• Alix-Panabieres C, Pantel K. Challenges in circulating tumour cell research. Nat Rev Cancer. 2014;14(9):623–631.
   PubMed Web of Science ®Google Scholar
• Bobek V, Matkowski R, Gurlich R, et al. Cultivation of circulating tumor cells in esophageal cancer. Folia HistochemCytobiol. 2014;52(3):171–177.
   PubMed Web of Science ®Google Scholar
• Qiao YY, Lin KX, Zhang Z, et al. Monitoring disease progression and treatment efficacy with circulating tumor cells in esophageal squamous cell carcinoma: A case report. World J Gastroenterol. 2015;21(25):7921–7928.
   PubMed Web of Science ®Google Scholar
• Matsushita D, Uenosono Y, Arigami T, et al. Clinical significance of circulating tumor cells in peripheral blood of patients with esophageal squamous cell carcinoma. Ann SurgOncol. 2015;22(11):3674–3680.
   Google Scholar
• Bratlie SO, Edebo A, Casselbrant A, et al. The renin-angiotensin system in Barrett’s esophagus. Scand J Gastroenterol. 2016;51(9):1037–1042.
   PubMed Web of Science ®Google Scholar
• Bratlie SO, Wallenius V, Edebo A, et al. Proteomic approach to the potential role of angiotensin ii in barrett dysplasia. Proteomics Clin Appl. 2019;13(4):e1800102.
   PubMed Web of Science ®Google Scholar
• Wu C, Wang Z, Song X, et al. Joint analysis of three genome-wide association studies of esophageal squamous cell carcinoma in Chinese populations. Nat Genet. 2014 Sep;46(9):1001–1006.
   PubMed Web of Science ®Google Scholar
• Slotta-Huspenina J, Berg D, Bauer K, et al. Evidence of prognostic relevant expression profiles of heat-shock proteins and glucose-regulated proteins in oesophageal adenocarcinomas. PLoS One. 2012;7(7):e41420.
   PubMed Web of Science ®Google Scholar
• Phelan JJ, MacCarthy F, Feighery R, et al. Differential expression of mitochondrial energy metabolism profiles across the metaplasia-dysplasia-adenocarcinoma disease sequence in Barrett’s oesophagus. Cancer Lett. 2014;354(1):122–131.
   PubMed Web of Science ®Google Scholar
• Pohler E, Craig AL, Cotton J, et al. The Barrett’s antigen anterior gradient-2 silences the p53 transcriptional response to DNA damage. Mol Cell Proteomics. 2004;3(6):534–547.
   PubMed Web of Science ®Google Scholar
• Manousopoulou A, Hayden A, Mellone M, et al. Quantitative proteomic profiling of primary cancer-associated fibroblasts in oesophageal adenocarcinoma. Br J Cancer. 2018;118(9):1200–1207.
   PubMed Web of Science ®Google Scholar
• Aichler M, Elsner M, Ludyga N, et al. Clinical response to chemotherapy in oesophageal adenocarcinoma patients is linked to defects in mitochondria. J Pathol. 2013;230(4):410–419.
   PubMed Web of Science ®Google Scholar
• O’Neill JR, Pak HS, Pairo-Castineira E, et al. Quantitative shotgun proteomics unveils candidate novel esophageal adenocarcinoma (EAC)-specific proteins. Mol Cell Proteomics. 2017;16(6):1138–1150.
   PubMed Web of Science ®Google Scholar
• Langer R, Ott K, Specht K, et al. Protein expression profiling in esophageal adenocarcinoma patients indicates association of heat-shock protein 27 expression and chemotherapy response. Clin Cancer Res. 2008;14(24):8279–8287.
   PubMed Web of Science ®Google Scholar
• Zhao J, Chang AC, Li C, et al. Comparative proteomics analysis of Barrett metaplasia and esophageal adenocarcinoma using two-dimensional liquid mass mapping. Mol Cell Proteomics. 2007;6(6):987–999.
   PubMed Web of Science ®Google Scholar
• Zaidi AH, Gopalakrishnan V, Kasi PM, et al. Evaluation of a 4-protein serum biomarker panel-biglycan, annexin-A6, myeloperoxidase, and protein S100-A9 (B-AMP)-for the detection of esophageal adenocarcinoma. Cancer. 2014;120(24):3902–3913.
   PubMed Web of Science ®Google Scholar
• Berndt U, Philipsen L, Bartsch S, et al. Comparative Multi-Epitope-Ligand-Cartography reveals essential immunological alterations in Barrett’s metaplasia and esophageal adenocarcinoma. Mol Cancer. 2010;9:177.
   PubMed Web of Science ®Google Scholar
• Song E, Zhu R, Hammoud ZT, et al. MS/MS quantitation of esophagus disease blood serum glycoproteins by enrichment with hydrazide chemistry and lectin affinity chromatography. J Proteome Res. 2014;13(11):4808–4820.
   PubMed Web of Science ®Google Scholar
• Mayampurath A, Song E, Mathur A, et al. Label-free glycopeptide quantification for biomarker discovery in human sera. J Proteome Res. 2014;13(11):4821–4832.
   PubMed Web of Science ®Google Scholar
• Kelly P, Appleyard V, Murray K, et al. Detection of oesophageal cancer biomarkers by plasma proteomic profiling of human cell line xenografts in response to chemotherapy. Br J Cancer. 2010;103(2):232–238.
   PubMed Web of Science ®Google Scholar
• Zaidi N, Kelly RJ. The management of localized esophageal squamous cell carcinoma: western approach. Chin Clin Oncol. 2017 Oct; 6(5):46.
   PubMed Web of Science ®Google Scholar
• Bandla S, Pennathur A, Luketich JD, et al. Comparative genomics of esophageal adenocarcinoma and squamous cell carcinoma. Ann Thorac Surg. 2012 Apr;93(4):1101–1106.
   PubMed Web of Science ®Google Scholar
• Pooja and Niranjan V. An integrative proteogenomics study to identify peptides and protein coding genes in esophageal squamous cell carcinoma. Curr Topics peptide protein Res. 2019;20:51–66.
   Google Scholar